Wedbush Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has downgraded Freeline Therapeutics (NASDAQ:FRLN) from Outperform to Neutral and lowered the price target from $8 to $5.
October 18, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Freeline Therapeutics has been downgraded from Outperform to Neutral by Wedbush, with a lowered price target from $8 to $5.
The downgrade from Outperform to Neutral by Wedbush indicates a less optimistic outlook for Freeline Therapeutics. The lowered price target from $8 to $5 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100